Lung Cancer

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses dacomitinib in patients with EGFR-positive non–small cell lung cancer.

Josephine L. Feliciano, MD, discusses the role of immunotherapy and the potential of targeted agents in small cell lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the clinical application of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses investigational biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer or RET-mutant medullary thyroid cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the PACIFIC trial results on the treatment landscape of stage III non–small cell lung cancer.

In the setting of advanced non–small cell lung cancer, the choice of up-front immunotherapy or chemotherapy, or combinations of both, is aided by findings from several trials.

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses the treatment of patients with non–small cell lung cancer who develop immune-related adverse events (irAEs).

Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.

Paul A. Bunn Jr, MD, discusses the potential for new agents to treat small cell lung cancer, the challenges involved in treating this population, and the ongoing search for biomarkers to guide treatment decisions.

In recent years, tyrosine kinase inhibitors that specifically target RET have entered the pipeline. Although none have yet received FDA approval, the promise of these agents has spurred interest in diagnostic assays.

Julie R. Brahmer, MD, provides an overview of the landscape of metastatic non–small cell lung cancer, specifically addressing the combination immunotherapy studies with the greatest impact.

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the use of chemoimmunotherapy in patients with non–small cell lung cancer (NSCLC).

D. Ross Camidge, MD, PhD, discusses the use of immunotherapy in patients with non–small cell lung cancer.

Patients with mutations in NTRK, RET, MET, HER2, and KRAS G12C have limited therapeutic options, but potentially promising agents are on the horizon.

Dustin M. Walters, MD, provides perspective on the treatment landscape of stage III non–small cell lung cancer.

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses challenges with immunotherapy in non–small cell lung cancer.

Josephine Louella Feliciano, MD, assistant professor of oncology, Johns Hopkins Medicine, discusses the use of nivolumab (Opdivo) in patients with small cell lung cancer (SCLC).

Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses managing immune-related adverse events (irAEs) in patients with non–small cell lung cancer (NSCLC).

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Ryan D. Gentzler, MD, highlights how chemotherapy remains a critical component of the metastatic non–small cell lung cancer treatment paradigm.

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved osimertinib for the frontline treatment of patients with inoperable or recurrent EGFR-positive non–small cell lung cancer.

Richard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).

The China National Drug Administration has approved alectinib for the treatment of patients with ALK-positive, advanced non–small cell lung cancer.

Jose M. Pacheco, MD, assistant professor, Medicine/Medical Oncology, Colorado University School of Medicine, discusses second-line therapy for patients with ALK-positive non–small cell lung cancer (NSCLC).

Ryan D. Gentzler, MD, assistant professor, Division of Hematology/Oncology, University of Virginia Health System, discusses the role of chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC).